To rule out this possibility, we tested the effect of AKT inhibitor and GSK-3β inhibitor (CHIR-9902) co-treatment on the p21 level in PTEN-deficient CRC cells. The gene discussed is CDKN1A; the disease is colorectal carcinoma.